Merck & Co., Inc. (NYSE:MRK) was added to Wells Fargo’s Q1 2026 Tactical Ideas List due to upcoming key events. MRK rose 8% in 2025 but faces patent loss for Keytruda in 2028. Recent acquisitions, like Cidara Therapeutics, bolster MRK’s pipeline. The company’s dividend remains stable. MRK focuses on prescription medicines and vaccines globally.

Investors should consider MRK’s potential but also explore other AI stocks with greater upside. For undervalued AI stock options, check out the best short-term AI stock report. For more investment opportunities, explore the 12 Best Income Stocks to Buy Now and 20 Best Performing Dividend Stocks in 2025. No disclosures were made.

Read more at Yahoo Finance: Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts